Screener
UroGen Pharma URGN Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Depreciation and amortization | 153 | 152 |
| Accrued financing on prepaid forward obligation | 2,050 | 123 |
| Accretion on marketable securities | (250) | (1,640) |
| Share-based compensation | 9,958 | 5,802 |
| Amortization of discount on long-term debt | 1,178 | 774 |
| Amortization of right-of-use assets | 1,167 | 941 |
| Acquisitions of IPR&D | — | 3,128 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's stock-based comp?
- UroGen Pharma (URGN) reported stock-based comp of $5.33M in Q2 2026.
- How has UroGen Pharma's stock-based comp changed year-over-year?
- UroGen Pharma's stock-based comp increased by 95.1% year-over-year, from $2.73M to $5.33M.
- What is the long-term trend for UroGen Pharma's stock-based comp?
- Over 4 years (2021 to 2025), UroGen Pharma's stock-based comp has grown at a -15.2% compound annual growth rate (CAGR), from $23.11M to $11.96M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about UroGen Pharma's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude